Table 2. First-line treatment.
| Variables | n (%) | P | |
| EP+A group (N=133) | EP group (N=92) | ||
| EP+A, atezolizumab plus EP chemotherapy; EP, EP chemotherapy; PCI, prophylactic cranial irradiation. | |||
| Chemotherapy regimen | 0.586 | ||
| Etoposide + cisplatin |
51 (38.3) | 32 (34.8) | |
| Etoposide + carboplatin | 82 (61.7) | 60 (65.2) | |
| Induction cycles | 0.546 | ||
|
4.64±1.58 | 4.47±1.73 | |
| Median | 5.00 | 4.00 | |
| P25−P75 | 4.00−6.00 | 4.00−6.00 | |
| Min−Max | 1.00−8.00 | 1.00−8.00 | |
| Induction ≥4 cycles | 0.585 | ||
| Yes | 106 (79.7) | 76 (82.6) | |
| No | 27 (20.3) | 16 (17.4) | |
| Atezolizumab doses received | − | ||
|
6.17±3.90 | − | |
| Median | 5.00 | − | |
| P25−P75 | 4.00−8.00 | − | |
| Min−Max | 1.00−17.00 | − | |
| Atezolizumab maintenance doses received ≥1 | <0.001 | ||
| Yes | 58 (43.6) | 0 (0) | |
| No | 75 (56.4) | 92 (100) | |
| Received thoracic radiotherapy | 0.036 | ||
| Yes | 26 (19.5) | 32 (34.8) | |
| No | 89 (66.9) | 49 (53.3) | |
| Unknown | 18 (13.5) | 11 (12.0) | |
| Received therapeutic cranial irradiation | 0.186 | ||
| Yes | 18 (13.5) | 21 (22.8) | |
| No | 97 (72.9) | 61 (66.3) | |
| Unknown | 18 (13.5) | 10 (10.9) | |
| Received PCI | 0.400 | ||
| Yes | 5 (3.8) | 7 (7.6) | |
| No | 110 (82.7) | 75 (81.5) | |
| Unknown | 18 (13.5) | 10 (10.9) | |